Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
NCT05198310 is registered in ClinicalTrials.gov with Kiniksa Pharmaceuticals, Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
- Lead sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 14, 2021
- Completion date
- May 6, 2024
- Enrollment
- 145 (actual)
- Sites
- 42
Conditions
As the registry lists them; a condition with its own page is linked.